생물정보학 시장의 글로벌 AI - 2030년까지의 산업 동향 및 예측

생물정보학 시장 분석 및 규모에 대한 AI

유전자 시퀀싱 비용의 감소는 시장 수요를 증가시켰습니다. 더 나은 건강 서비스를 위한 의료비 지출 증가도 시장 성장에 기인합니다. 주요 시장 참여자들은 이 중요한 기간 동안 다양한 서비스 출시와 서비스 승인에 매우 집중하고 있습니다. 또한, 생물정보학에 대한 수요 증가와 생물정보학에 대한 공공-민간 부문 자금 지원 증가도 시장 수요 증가에 기여하고 있습니다.

생물정보학 분야의 AI 시장은 시장 참여자의 증가와 고급 서비스의 가용성으로 인해 예측 연도에 성장하고 있습니다. 이와 함께 제조업체는 시장에서 새로운 서비스를 출시하기 위한 R&D 활동에 참여하고 있습니다. 생물정보학 기술의 발전이 시장 성장을 더욱 촉진하고 있습니다. 그러나 생물정보학 분야의 계측기 비용과 사이버 보안 문제가 예측 기간 동안 생물정보학 분야의 AI 시장 성장을 방해할 수 있습니다.

Data Bridge Market Research는 2022년 글로벌 AI in bioinformatics 시장이 253만 달러 규모로 평가되고 2030년까지 2억 1,738만 달러에 도달할 것으로 예상되며 2023-2030년 예측 기간 동안 42.7%의 CAGR을 기록할 것으로 분석했습니다. "서비스"는 생물정보학에서 핸드헬드 AI 사용을 상용화하기 위한 기술 경로의 빠른 발전으로 인해 AI in bioinformatics 시장에서 가장 큰 기술 세그먼트를 차지합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함됩니다.

보고 범위 및 시장 세분화

시장 정의

생물정보학은 생물학적 분자의 시퀀스 분석과 관련된 하위 분야입니다. 일반적으로 유전자, DNA, RNA 또는 단백질을 말하며, 특히 단백질의 유전자와 다른 시퀀스와 유기체 내 또는 유기체 간의 다른 시퀀스를 비교하고, 유기체 간의 진화적 관계를 살펴보고, DNA와 단백질 시퀀스에 존재하는 패턴을 사용하여 그 기능을 파악하는 데 유용합니다.

생물정보학은 컴퓨터 프로그래밍, 빅데이터, 분자생물학을 결합한 것으로, 과학자들이 생물학적 데이터의 패턴을 이해하고 식별할 수 있도록 해줍니다. 특히 게놈과 DNA 시퀀싱을 연구하는 데 유용합니다. 과학자들이 방대한 양의 데이터를 정리할 수 있기 때문입니다.

유전학에서 독성학, 진균학, 방사선생물학에 이르기까지 전문화할 수 있는 생물학 분야가 수십 개 있습니다. 그리고 그 중에서도 생물정보학은 생물학적 정보를 식별, 평가, 저장 및 검색할 수 있는 흥미로운 분야 중 하나입니다. 학제간 연구 분야로서 컴퓨터 과학, 통계학, 생물학의 다양한 응용 프로그램을 통합하여 DNA 시퀀싱, 단백질 분석, 진화 유전학 등과 같은 생물학적 데이터를 이해하기 위한 소프트웨어 응용 프로그램을 개발합니다.

In the coming future, important decisions related to bioinformatics on drug discovery will be made by individuals who not only understand biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify the quality target.

Global AI in Bioinformatics Market Dynamics

Drivers

• Growing demand for bioinformatics

As genomics focused, pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight into molecular underpinnings of individual tumors and specific receptors. Informatics is essential in biological research, which involves biologists who learn programming, or computer programmers, mathematicians, or database managers to learn the foundations of biology.

• Reduction in the genetic sequencing cost

The strong demand for decreasing the cost of genomics and biomarker prediction has contributed to the creation of high-throughput genome sequencing, which often goes by the name next-generation sequencing (NGS). Thousands or millions of sequences in a single bioinformatics cycle are generated simultaneously. Dramatic upgrades to industrial NGS technologies have culminated in dramatic cutbacks in DNA sequencing cost-per-base. Thus recently, the main sequencing techniques have become the key subject of research, with sample design optimization taking a secondary function.

• Increasing public-private sector funding for bioinformatics

In order to improve the workflow for bioinformatics, the federal agencies, the public and the private agencies are providing funds in order to carry out bioinformatics projects and to scientists for research purposes. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes. Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which, in turn, have improved the quality of these services.

 Opportunities

• Strategic initiatives of key players

The dramatic rise in the quality of research coupled with increasing research opportunities is because of various strategic initiatives taken by key market players. They are taking initiatives such as product launches, collaborations, mergers, acquisitions and many more over the years and are expected to lead and create more opportunities in the market.

By successfully working with new technology firms to ensure continued growth, creativity and viability in the industry, healthcare product suppliers have a huge opportunity. Health enterprises that implement technology-enabled technologies will explore new modes of goods for patient care, streamline processes and engage patients more.

Companies to discover and develop advanced bioinformatics products and these companies are launching new initiatives and collaborating with other key players to deliver more reliable results and services.

• Advancement in bioinformatics technology

The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, AI based bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology, up-gradation of instruments and techniques is also needed, moreover, the bioinformatics market has a vast potential to upgrade in various applications and there are high chances of the advancement of bioinformatics techniques in the forecasted period.

 Restraints/Challenges

• High cost of instrumentation

The cost of the device plays a major factor in the market. The AI based bioinformatics instrument is highly sophisticated and needs high validation and other specification, which increase. Genomics instruments are also equipped with advanced features and functionalities and are thus priced at a premium, ranging between USD 10–20 million. As pharmaceutical companies and research laboratories require many such systems, their capital expenditure on procuring multiple genomic instruments is very high. In the case of small and medium-sized pharmaceutical companies and research laboratories, it is not feasible for them to make such high investments in multiple genomics instruments. Hence, the high cost of AI based equipment is expected to restrain the market growth.

• Lack of skilled professionals to perform AI based bioinformatics technology

One of biology's most rapidly developing fields of study is bioinformatics, which involves developing and using computational tools for collecting, archiving, organizing, analyzing, and visualizing biological data. The advancement of technology has made it possible to reach the level of next-generation analysis from conventional data analysis methods. The advancement of the technology of bioinformatics requires various skill sets for its handling. As the bioinformatics platforms are highly automated and costly machines, the improper handling of such machines can damage their parts which can hamper achieving analysis and visualisation of biological data. Thereby, it will proportionally hamper the result of data processing. The dearth of skilled professionals having adequate skills and knowledge to perform next-generation sequencing, therefore, hampers the growth of the market.

This AI in bioinformatics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the AI in bioinformatics market contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In June 2022, SOPHiA GENETICS, a leader in data-driven medicine, announced at the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications. With this certification, the SOPHiA DDM™ Platform is now IVD-ready to support all applications and modules designed for diagnostic purposes in the European Union and other markets recognizing this certification. This has helped the company to increase its global presence in the market
• In December 2021, JADBio and BioLizard announced their partnership. BioLizard is agile bioinformatics and AI/ML company globally servicing clients in the life sciences, biotechnology and pharmaceutical industries. JADBio is a robust Automated Machine Learning platform that allows intuitive, timely and interactive creation of ML predictive models on BioMedical and Multi-omics data while allowing for knowledge (biomarker signature) discovery through its vast range of reporting and analysis. This has helped the company to expand its products and services portfolio in the market.

Global AI in Bioinformatics Market Scope

The AI in bioinformatics market is segmented on the basis of offering, type, products and services, application and sector. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

• Services
•  Software
•  Others

Type

• Machine Learning
• Deep Learning
• Others

Products and Services

• Bioinformatics Services
• Bioinformatics Platforms
• Knowledge Management Tools

Application

• Genomics
• Chemoinformatics & Drug Design
• Proteomics
• DNA Sequencing
• System Biology
• Transcriptomics
• Text Mining
• Microarrays
• Metabolomics
• Others

Sector

• Medical Biotechnology
• Animal Biotechnology
• Plant Biotechnology
• Environmental Biotechnology
• Forensic Biotechnology
• Others

Global AI in Bioinformatics Analysis/Insights

The AI in bioinformatics market is analyzed and market size insights and trends are provided by country, offering, type, products and services, application and sector as referenced above.

The countries covered in the  AI in bioinformatics market report are U.S., Canada, Mexico in North America, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, rest of Europe in Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, rest of Asia-Pacific in Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and rest of Middle East and Africa (MEA) in Middle East and Africa, Brazil, Argentina and rest of South America in South America.

North America is expected to dominate the global AI in bioinformatics market due to the rising demand for advanced technology and drug development & design, which have accelerated the market growth. To cope with the increasing demand, companies and market players are initiating various strategies such as product launch, advancement, acquisition agreements and others which is expected to dive the market growth.

Asia-Pacific is expected to show significant growth in AI in Bioinformatics market during the forecast period of 2023 to 203o due to rapidly increasing government investments in healthcare infrastructure and AI research.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and AI in Bioinformatics Market Share Analysis

The AI in bioinformatics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus on the AI in bioinformatics market.

The major players covered in the AI in bioinformatics market report are:

• JADBio (U.S.)
• Gnosis Data Analysis (Israel)
• Fios Genomics (U.K.)
• SOPHiA GENETICS (Switzerland)
• Biomax Informatics Inc. (U.S.)
• DNASTAR (U.S.)
• Ardigen (Parent Company Selvita Group) (Poland)
• Source BioScience (U.K.)
• QIAGEN (Germany)
• NeoGenomics Laboratories (U.S.)
• CelbridgeScience (U.S.)
• Eurofins Scientific (Luxembourg)
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)
• Insilico Medicine (U.S.)
• Strand Life Sciences (India)
• Dassault Systèmes (France)
• iNDX.Ai (U.S.)
• Paige AI, Inc. (U.S.)
• SomaLogic Operating Co., Inc. (미국)

SKU-69028